Adults with primary aldosteronism had improvements ... releasing factor type 1 receptor to treat congenital adrenal hyperplasia, according to a press release. ORLANDO — Nearly one-quarter ...
Hosted on MSN1mon
Crinetics falls after mid-stage trial data adrenal disorder therapyits experimental therapy for congenital adrenal hyperplasia (CAH). CAH, a group of genetic disorders affecting adrenal glands, is characterized by excessive levels of androstenedione (A4), a ...
Primary endpoints included change from baseline ... Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. For more information about ...
Detailed price information for Crinetics Pharmaceuticals Inc (CRNX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback